Et fase 1-dosis-eskaleringsstudie af SLV 154 i forsøgspersoner med metastatiske faste tumorer
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-154. Once the initial RDR is established in the Phase 1a portion of this study, further development in the Phase 1b expansion portion of this study will be considered in patients with specific cancers. In the Phase 1b part of this study, enrollment of each tumor-specific cohort will be performed using a Simon 2-stage optimal design.
SLV-154 will be administered intravenously (IV) in repeated 3-week cycles. Treatment will continue until progressive disease or discontinuation.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Langdon L Miller, MD
- Telefonnummer: 908-906-6471
- E-mail: lmiller@solvetx.com
Undersøgelse Kontakt Backup
- Navn: Hong Ren, MD
- Telefonnummer: 425-894-2558
- E-mail: hren@solvetx.com
Studiesteder
-
-
California
-
Newport Beach, California, Forenede Stater, 92663
- Rekruttering
- Hoag Memorial Hospital Presbyterian
-
Kontakt:
- Cindy Do, BSN, RN
- Telefonnummer: 949-764-4624
- E-mail: cindy.do@hoag.org
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University
-
Kontakt:
- Sara Mitchum
- Telefonnummer: 314-273-8602
- E-mail: saram@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Forenede Stater, 08816
- Rekruttering
- Astera Cancer Care
-
Kontakt:
- Percy Yeung
- Telefonnummer: 732-387-3378
- E-mail: percy.yeung@asterahealthcare.org
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Roisin O'Cearbhaill, MD
- Telefonnummer: 646-888-4227
- E-mail: ocearbhr@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- University Hospitals Cleveland Medical Center
-
Kontakt:
- Afshin Dowlati, MD
- Telefonnummer: 212-844-6031
- E-mail: afshin.dowlati@UHhospitals.org
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The James Outpatient Care West Center
-
Kontakt:
- Adam Roan
- Telefonnummer: 614-685-0587
- E-mail: Adam.Roan@osumc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19111
- Rekruttering
- Fox Chase Cancer Center
-
Kontakt:
- Dajah White-Dumpson
- Telefonnummer: 215-214-1600
- E-mail: Dajah.White-Dumpson@fccc.edu
-
Kontakt:
- Shannon Fabrie
- Telefonnummer: 215-728-3620
- E-mail: shannon.fabrie@fccc.edu
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
Kontakt:
- Rabia Khan
- Telefonnummer: 713-563-4667
- E-mail: RKhan@mdanderson.org
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Oncology Consultants
-
Kontakt:
- Julio Peguero, MD
- Telefonnummer: 713-600-0900
- E-mail: jPeguero@oncologyconsultants.com
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Mays Cancer Center; University of Texas Health San Antonio
-
Ledende efterforsker:
- Daruka Mahadevan
-
Kontakt:
- Daruka Mahadevan, MD
- Telefonnummer: 210-450-1000
- E-mail: mahadevand@uthscsa.edu
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- University of Washington / Fred Hutchinson Cancer Center
-
Kontakt:
- Phase 1 Clinical Trials
- Telefonnummer: 206-606-7551
- E-mail: phase1clinicaltrial@fredhutch.org
-
Tacoma, Washington, Forenede Stater, 98405
- Rekruttering
- Northwest Medical Specialties, PLLC
-
Kontakt:
- CarrieAnn Brown
- Telefonnummer: 253-428-8700
- E-mail: cbrown@nwmsonline.com
-
Kontakt:
- Kiersten Peart
- Telefonnummer: 253-428-8700
- E-mail: kpeart@nwmsonline.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Men or women (as appropriate for cancer type) of age ≥12 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
- Presence of metastatic or recurrent locally advanced cancer.
- Presence of radiographically measurable disease.
- Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
- Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
- Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
- Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
- Adequate hematological profile.
- Adequate coagulation profile.
- Adequate hepatic profile.
- Adequate renal function.
- Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
- For female subjects of childbearing potential, a negative serum pregnancy test.
- For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
- For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
- Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
- Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion Criteria:
- Unstable malignancy involving the central nervous system.
- Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
- Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
- Significant cardiovascular event or comorbidity.
- Significant screening ECG abnormalities.
- Pregnancy or breastfeeding.
- Major surgery within 3 weeks before the start of study therapy.
- Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
- Concurrent participation in another therapeutic or imaging clinical trial.
- Other conditions likely to interfere with a subject's ability to participate in the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dose Level 1
0.75 mg/kg |
SLV-154 |
|
Eksperimentel: Dose Level 2
1.5 mg/kg |
SLV-154 |
|
Eksperimentel: Dose Level 3
3.0 mg/kg |
SLV-154 |
|
Eksperimentel: Dose Level 4
4.0 mg/kg |
SLV-154 |
|
Eksperimentel: Dose Level 5
5.0 mg/kg |
SLV-154 |
|
Eksperimentel: Dose Level 6
6.5 mg/kg |
SLV-154 |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 1a: MTD and/or RDR
Tidsramme: Through the duration of treatment, up to approximately 18 months
|
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154. |
Through the duration of treatment, up to approximately 18 months
|
|
Phase 1b: Objective response rate (ORR)
Tidsramme: Through the duration of treatment, up to approximately 18 months
|
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR). |
Through the duration of treatment, up to approximately 18 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
SLV-154 administration
Tidsramme: Through the duration of treatment, up to approximately 18 months
|
SLV-154 drug administration as assessed by prescribing records |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Safety
Tidsramme: Through the duration of treatment, up to approximately 18 months
|
Collection of type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign/oxygen saturation abnormalities; adverse electrocardiogram (ECG) findings; DLTs; serious adverse events (SAEs); adverse events of special interest (AESIs); or adverse events (AEs) leading to interruption, modification, or discontinuation of study drug administration. |
Through the duration of treatment, up to approximately 18 months
|
|
Evaluation of use of concomitant medications
Tidsramme: Through the duration of treatment, up to approximately 18 months
|
Type, frequency, and timing of use of supportive care and other concomitant medications |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Pharmacokinetics
Tidsramme: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Evaluation of the pharmacokinetic profile of SLV-154 |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Immunogenicity
Tidsramme: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Measurement of changes in titers of circulating SLV 154-reactive antibodies (as assessed using immunoassay methods) |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Time to Response (TTR)
Tidsramme: Up to approximately 36 months
|
TTR: interval from the start of study drug administration to the first documentation of objective tumor regression |
Up to approximately 36 months
|
|
Duration of Response (DOR)
Tidsramme: Up to approximately 36 months
|
DOR: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
4-month progression-free survival (PFS4)
Tidsramme: Up to approximately 36 months
|
PFS4: proportion of subjects who are alive and have not experienced disease progression at 4 months after the start of study drug administration |
Up to approximately 36 months
|
|
6-month progression-free survival (PFS6)
Tidsramme: Up to approximately 36 months
|
PFS6: proportion of subjects who are alive and have not experienced disease progression at 6 months after the start of study drug administration |
Up to approximately 36 months
|
|
Time to treatment failure (TTF)
Tidsramme: Up to approximately 36 months
|
TTF: interval from the start of study drug administration to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause |
Up to approximately 36 months
|
|
Overall survival (OS)
Tidsramme: Up to approximately 36 months
|
OS: interval from the start of study drug administration to death from any cause |
Up to approximately 36 months
|
|
Disease benefit ratio (DBR)
Tidsramme: Up to approximately 36 months
|
DBR: proportion of subjects who experience CR, PR, or stable disease with tumor reduction (SDTR) |
Up to approximately 36 months
|
|
Progression free survival (PFS)
Tidsramme: Up to approximately 36 months
|
PFS: interval from the start of study drug administration to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
Duration of disease benefit (DDB)
Tidsramme: Up to approximately 36 months
|
DDB: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause in subjects with disease benefit |
Up to approximately 36 months
|
|
Percent change in tumor dimensions
Tidsramme: Up to approximately 36 months
|
percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions |
Up to approximately 36 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- SLV-154-01Tx
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Results will be presented in clinical study reports and publications. Individual participant data will not be shared with other researchers.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .